MX2021001976A - Polipéptidos anti-her2 y métodos de uso de los mismos. - Google Patents
Polipéptidos anti-her2 y métodos de uso de los mismos.Info
- Publication number
- MX2021001976A MX2021001976A MX2021001976A MX2021001976A MX2021001976A MX 2021001976 A MX2021001976 A MX 2021001976A MX 2021001976 A MX2021001976 A MX 2021001976A MX 2021001976 A MX2021001976 A MX 2021001976A MX 2021001976 A MX2021001976 A MX 2021001976A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- variable region
- antibody variable
- methods
- bbb
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721505P | 2018-08-22 | 2018-08-22 | |
| PCT/US2019/047728 WO2020041604A1 (en) | 2018-08-22 | 2019-08-22 | Anti-her2 polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001976A true MX2021001976A (es) | 2021-06-08 |
Family
ID=67989062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001976A MX2021001976A (es) | 2018-08-22 | 2019-08-22 | Polipéptidos anti-her2 y métodos de uso de los mismos. |
Country Status (15)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| US20250066449A1 (en) * | 2021-12-31 | 2025-02-27 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| KR20240067001A (ko) * | 2022-10-28 | 2024-05-16 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| JP2025540336A (ja) * | 2022-12-08 | 2025-12-11 | アデル,インク | 抗タウ抗体及びペプチドを含む融合体とその用途 |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) * | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| WO2015191934A2 (en) * | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| JP7021955B2 (ja) * | 2015-06-24 | 2022-03-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| RS63818B1 (sr) * | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2019032955A1 (en) * | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
-
2019
- 2019-08-22 EP EP19769934.1A patent/EP3840781A1/en active Pending
- 2019-08-22 CN CN201980068845.5A patent/CN113286610A/zh active Pending
- 2019-08-22 WO PCT/US2019/047728 patent/WO2020041604A1/en not_active Ceased
- 2019-08-22 TW TW108130121A patent/TW202017947A/zh unknown
- 2019-08-22 AR ARP190102390A patent/AR115998A1/es unknown
- 2019-08-22 MX MX2021001976A patent/MX2021001976A/es unknown
- 2019-08-22 AU AU2019326545A patent/AU2019326545A1/en not_active Abandoned
- 2019-08-22 IL IL326298A patent/IL326298A/en unknown
- 2019-08-22 KR KR1020217008163A patent/KR20210074279A/ko not_active Ceased
- 2019-08-22 CA CA3141815A patent/CA3141815A1/en active Pending
- 2019-08-22 SG SG11202101436SA patent/SG11202101436SA/en unknown
- 2019-08-22 EA EA202190603A patent/EA202190603A1/ru unknown
- 2019-08-22 BR BR112021002953-2A patent/BR112021002953A2/pt unknown
- 2019-08-22 JP JP2021510094A patent/JP2021534220A/ja active Pending
-
2021
- 2021-02-16 IL IL280922A patent/IL280922B2/en unknown
- 2021-02-18 US US17/178,595 patent/US20220002436A1/en active Pending
-
2024
- 2024-07-25 JP JP2024119250A patent/JP7818042B2/ja active Active
-
2026
- 2026-01-07 AU AU2026200081A patent/AU2026200081A1/en active Pending
- 2026-02-06 JP JP2026018549A patent/JP2026086616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL326298A (en) | 2026-04-01 |
| JP2021534220A (ja) | 2021-12-09 |
| KR20210074279A (ko) | 2021-06-21 |
| US20220002436A1 (en) | 2022-01-06 |
| IL280922B1 (en) | 2026-03-01 |
| EA202190603A1 (ru) | 2021-07-14 |
| CA3141815A1 (en) | 2020-02-27 |
| JP2026086616A (ja) | 2026-05-26 |
| CN113286610A (zh) | 2021-08-20 |
| JP7818042B2 (ja) | 2026-02-19 |
| IL280922B2 (en) | 2026-07-01 |
| AU2019326545A1 (en) | 2021-03-11 |
| AR115998A1 (es) | 2021-03-25 |
| IL280922A (en) | 2021-04-29 |
| TW202017947A (zh) | 2020-05-16 |
| EP3840781A1 (en) | 2021-06-30 |
| WO2020041604A1 (en) | 2020-02-27 |
| JP2024150674A (ja) | 2024-10-23 |
| BR112021002953A2 (pt) | 2021-05-11 |
| AU2026200081A1 (en) | 2026-01-29 |
| SG11202101436SA (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115998A1 (es) | Polipéptidos anti-her2 y métodos de uso de los mismos | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| CL2017002244A1 (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015). | |
| MX2019001651A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
| CL2022000127A1 (es) | Anticuerpos que se fijan a gprc5d | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| PY1888702A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CO2021008568A2 (es) | Anticuerpos que se unen a cd3 | |
| MX2022006758A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| DOP2018000281A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| CL2018001175A1 (es) | Anticuerpos anti-il1rap, moleculas de union de antigenos bioespecificos que unen il1rap y cd3 y usos de los mismos. | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| BR112019005697A2 (pt) | anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16 | |
| MX2019012364A (es) | Proteinas de union a antigenos trem2 y usos de estas. | |
| AR102522A1 (es) | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a | |
| PE20190562A1 (es) | Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral | |
| TR201809571T4 (tr) | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| MX2019014361A (es) | Dominios de ig heterodimerizantes. | |
| MX2009007571A (es) | Vacuna. | |
| CL2020002585A1 (es) | Proteínas de fusión del factor de diferenciación de crecimiento 15 | |
| MX2020004220A (es) | Anticuerpos anti-glico-muc1 y sus usos. |